| Personalis to Participate at Upcoming Investor Conferences | 08/22 16:01 | businesswire.com |
| Personalis: Resetting My Strategy Following The Q2 Beat | 08/18 07:47 | seekingalpha.com |
| Personalis, Inc. (PSNL) Hit a 52 Week High, Can the Run Continue? | 08/13 10:16 | zacks.com |
| Personalis, Inc. (PSNL) Q2 2024 Earnings Call Transcript | 08/07 23:09 | seekingalpha.com |
| Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates | 08/07 18:30 | zacks.com |
| Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing | 07/11 09:00 | globenewswire.com |
| Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference | 06/18 16:01 | businesswire.com |
| Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call | 06/13 08:00 | businesswire.com |
| ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring | 06/04 16:05 | businesswire.com |
| Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus | 05/31 09:05 | businesswire.com |